

*Current Strategies in the Treatment of Cardiovascular Diseases:  
The Role of Beta-Blocker Therapy*

Edited proceedings of an educational symposium, sponsored by the University of Texas Southwestern Medical Center at Dallas, and held during the 68th Scientific Sessions of the American Heart Association, November 14, 1995, in Anaheim, California.

**SYMPOSIUM FACULTY**

**Norman M. Kaplan, MD**

Professor of Internal Medicine  
University of Texas Southwestern Medical Center  
Dallas, TX

**Stephen S. Gottlieb, MD**

Associate Professor of Medicine  
University of Maryland School of Medicine  
Baltimore, MD

**Finn Waagstein, MD, PhD**

Associate Professor of Medicine  
Division of Cardiology and Wallenberg Laboratory  
Sahlgren's Hospital  
Göteborg, Sweden

This special report was supported by an unrestricted educational grant from Astra Pharmaceuticals, Inc. The publisher of this special report assumes responsibility for fair balance, independence, objectivity, and scientific accuracy. Astra Pharmaceuticals, Inc. does not have any control over the content of this special report.

*Publisher's Note:* The opinions expressed in this special report are those of the panelists and are not attributable to the sponsor or the publisher, editor, or editorial board of *The American Journal of Managed Care*. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this special report are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the panelists and the authors or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.